December 23rd, 2024: FDA raises concerns about unapproved compounded GLP-1 drugs causing hospitalizations The FDA has expressed concerns about the use of unapproved GLP-1 drugs like semaglutide (Ozempic) and tirzepatide for weight loss
Its important to strictly adhere to your doctors instructions about taking Ozempic
in: PubMed | Google Scholar | Published October 16, 2025 - More info Long-chain fatty acid oxidation disorders (LC-FAODs) cause energy deficits in heart and skeletal muscle that are only partially corrected by current medium-chain lipid therapies such as triheptanoin
Its not in any official guidance, but it makes practical sense, and consistent administration matters more than always using the same site
Cohen carefully evaluates each patient's unique needs and lifestyle before recommending GLP-1 therapy, ensuring it aligns with their weight loss and health goals
However, the exact mechanisms responsible for the BP-lowering effects and loss of BW associated with these two agents have not been fully understood